
Valion Bio fell 98.6% from $37.75 to $0.54, behind the S&P 500's +10.0%. Its worst day was Apr 28 (−27.9%), and its low came Nov 5 at $0.50.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Valion Bio shares rose 24.5%, while the S&P 500 fell 0.8%.
+24.5% · S&P 500 −0.8%
Valion Bio closed at its highest level of the year, 76.2% above where the year started.
+11.8% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
EPS of $-37.25 was reported on $80,000.00 revenue.
−13.3% · S&P 500 −1.8%
Valion Bio shares fell 27.9%, while the S&P 500 fell 0.5%.
−27.9%, the year's worst day · S&P 500 −0.5%
EPS of $-55.75 was reported on $0.00 revenue.
−5.5% · S&P 500 −1.2%
The Committee’s focus on radiation/nuclear countermeasures addresses an important force protection and readiness challenge by emphasizing medical countermeasures that offer both prophylactic as well as therapeutic
−24.8% · S&P 500 +1.7%
Valion Bio shares fell 27.8%, while the S&P 500 fell 0.2%.
−27.8% · S&P 500 −0.2%
EPS of $-54.25 was reported on $0.00 revenue.
−4.2% · S&P 500 −0.5%
Valion Bio shares rose 27.5%, while the S&P 500 fell 0.1%.
+27.5% · S&P 500 −0.1%
Valion Bio closed at its lowest level of the year, 98.7% below where the year started.
−2.9% · S&P 500 −4.4%
Where it ended: a close of $0.54 on Nov 17, 2026. Up next: Q3 2026 earnings on Dec 1, 2026.
Nothing in the past 12 months.
All VBIO analyst actionsNothing in the past 12 months.
All VBIO dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VBIO and SPY from Benzinga historical bars. Not investment advice.